Abstract
Imatinib (IM) is highly effective in treatment of chronic myeloid leukemia (CML) but does not eliminate minimal residual disease (MRD), which remains a potential source of relapse. IM treatment effectively inhibits BCR–ABL kinase activity in CML cells, suggesting that additional kinase-independent mechanisms contribute to the presence of MRD. Bone marrow (BM) microenvironment protecting CML cells from IM treatment was investigated. Culturing CML cell line K562 in human stromal cell line HS-5-derived conditioned medium significantly inhibited apoptosis induced by IM, which was soluble factor-mediated drug resistance (SFM-DR). The BM stroma-derived soluble factors could enhance the resistance of K562 cells to IM by increasing Stat3 phosphorylation on tyrosine 705 and subsequently increasing the expression of anti-apoptotic proteins and P-glycoprotein (P-gp) in K562 cells. Furthermore, the reversal effect of oroxylin A, a naturally monoflavonoid isolated from the root of Scutellaria baicalensis Georgi, in K562 cells within the SFM-DR model was detected. After treatment of weakly toxic concentration of oroxylin A, the apoptosis of K562 cells induced by IM was increased dramatically through suppressing Stat3 pathway. In addition, the in vivo study showed that oroxylin A potentiates the inhibitory effects of IM on leukemia development by suppressing Stat3 pathway in the K562 xenograft model. In conclusion, IM-induced resistance in K562 cells within the SFM-DR model correlated with increasing Stat3 signaling and upregulating P-gp expression through Stat3 pathway. Additionally, oroxylin A improved the sensitivity of K562 cells to IM in SFM-DR model and in vivo, and the underlying mechanism attributed to the suppression of Stat3 pathway, which suggested oroxylin A might be a promising agent for treatment designed to eradicate MRD in CML patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7(10):3169–3175. doi:10.1158/1535-7163.MCT-08-0314
Bixby D, Talpaz M (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25(1):7–22. doi:10.1038/leu.2010.238
Bournazou E, Bromberg J (2013) Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat 2(2):e23828. doi:10.4161/jkst.23828
Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D (2008) Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas. J Oncol 2008:219241. doi:10.1155/2008/219241
Coppo P, Flamant S, De Mas V et al (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134(2):171–179. doi:10.1111/j.1365-2141.2006.06161.x
Cortes JE, Nicolini FE, Wetzler M et al (2013) Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 13(5):584–591. doi:10.1016/j.clml.2013.03.020
Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11(7):1156–1166. doi:10.1101/gr.184901
Galimberti S, Cervetti G, Guerrini F et al (2005) Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet 162(1):57–62. doi:10.1016/j.cancergencyto.2005.01.015
Gao Y, Lu N, Ling Y et al (2010) Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. J Cancer Res Clin Oncol 136(5):667–675. doi:10.1007/s00432-009-0705-2
Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448–457
Glowacki S, Synowiec E, Blasiak J (2013) The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors. Int J Mol Sci 14(8):16348–16364. doi:10.3390/ijms140816348
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174. doi:10.1038/nm1483
Li HB, Chen F (2005) Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074(1–2):107–110
Litzow MR (2006) Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 130(5):669–679. doi:10.1043/1543-2165(2006)130[669:IROAO]2.0.CO;2
Liu Y, Zhang SP, Cai YQ (2007) Cytoprotective effects of selenium on cadmium-induced LLC-PK1 cells apoptosis by activating JNK pathway. Toxicol In Vitro Int J Publ Assoc BIBRA 21(4):677–684. doi:10.1016/j.tiv.2007.01.015
Mahon FX, Hayette S, Lagarde V et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68(23):9809–9816. doi:10.1158/0008-5472.Can-08-1008
Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM (2012) Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012:157496. doi:10.1155/2012/157496
Melo JV, Chuah C (2008) Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. hematology/the education program of the American Society of Hematology American Society of Hematology Education Program. 427–435. doi:10.1182/asheducation-2008.1.427
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA (2012a) Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 36(6):756–763. doi:10.1016/j.leukres.2011.12.002
Nair RR, Tolentino JH, Hazlehurst LA (2012b) Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2:30. doi:10.3389/fonc.2012.00030
Nambu T, Araki N, Nakagawa A et al (2010) Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci 101(1):137–142. doi:10.1111/j.1349-7006.2009.01365.x
Roecklein BA, Torok-Storb B (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85(4):997–1005
Samanta A, Perazzona B, Chakraborty S et al (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463–472. doi:10.1038/leu.2010.287
Song X, Chen Y, Sun Y et al (2012) Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep PR 64(5):1189–1199
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J (2013) The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2013.07.017
Traer E, MacKenzie R, Snead J et al (2012) Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 26(5):1140–1143. doi:10.1038/leu.2011.325
Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Ther Targets 7(2):215–234. doi:10.1517/14728222.7.2.215
Wang H, Zhao L, Zhu LT et al (2013) Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3 K/Akt signaling pathway. Mol Carcinog. doi:10.1002/mc.22052
Weisberg E, Wright RD, McMillin DW et al (2008) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 7(5):1121–1129. doi:10.1158/1535-7163.MCT-07-2331
Yang HY, Zhao L, Yang Z et al (2012) Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol Carcinog 51(2):185–195. doi:10.1002/mc.20789
Zhang X, Xiao W, Wang L, Tian Z, Zhang J (2011) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS ONE 6(6):e20965. doi:10.1371/journal.pone.0020965
Zhang Y, Zhao L, Li X et al (2013) V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. Arch Toxicol. doi:10.1007/s00204-013-1085-6
Zhao L, Chen Z, Wang J et al (2010) Synergistic effect of 5-fluorouracil and the flavonoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 65(3):481–489. doi:10.1007/s00280-009-1053-2
Zhu B, Zhao L, Zhu L et al (2012) Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway. Toxicol Appl Pharmacol 259(3):387–394. doi:10.1016/j.taap.2012.01.019
Zhu L, Zhao L, Wang H et al (2013) Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett 219(2):107–115. doi:10.1016/j.toxlet.2013.01.019
Acknowledgments
This work was supported by the National Science & Technology Major Project (No. 2012ZX09103101-050 and 2012ZX09304-001), the National Natural Science Foundation of China (No. 91029744 and 81001452), Natural Science Foundation of Jiangsu Province, China (No. BK2010432), the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University(No. SKLNMZZJQ201302, SKLNMZZ201210), Program for Changjiang Scholars and Innovative Research Team in University (IRT1193), and Fundamental Research Funds for the Central Universities(No.JKP2013010).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, X., Miao, H., Zhang, Y. et al. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. Arch Toxicol 89, 121–136 (2015). https://doi.org/10.1007/s00204-014-1226-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-014-1226-6